Antipsychotic Drug Therapies: Matching primary care practice to clinical challenges

Bazelon Center for Mental Health Law. Primary care providers’ role in mental health. Link: https://tinyurl.com/y7rbxu3t

Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, et al. (1993) The de facto US mental and addictive disorders service system: Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Archives of General Psychiatry 50: 85–94. Link: https://tinyurl.com/yc7oyqqb

National Council for Behavioral Health (2017). The psychiatric shortage: causes and solutions. Link: https://tinyurl.com/ldbtnc2

Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, et al. (2004) Anti-psychotic drug associated weight gain and metabolic abnormalities: implications for increased mortality from schizophrenia. J Clin Psych 7: 4-18. Link: https://tinyurl.com/y7cbjcpl

Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, et al. (2017) Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 13: 757-777. Link: https://tinyurl.com/y9oc3up4

Scheer CE (2016) Differentiating antipsychotics. An overview of properties impacting drug selection. Western Schools SC Publishing. Link: https://tinyurl.com/y9k8oxqk

Sherling DH, Perumareddi P, Hennekens CH (2017) Clinical and policy implications of metabolic syndrome: the new silent killer. JCPT. Link: https://tinyurl.com/yddsbne5

Hennekens CH, Hennekens AR, Hollar D, Casey DE (2005) Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150: 1115-1121. Link: https://tinyurl.com/y9aem7dx

Newcomer JW, Hennekens CH (2007) Major mental illness and premature morbidity and mortality from cardiovascular disease: the need for new paradigms. JAMA 298: 1794-1796.

Lieberman JA, Stroup TS, McEvoy JP, Marvin SS, Rosenheck RA, et al. (2005) Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223. Link: https://tinyurl.com/y7ayedp5

Halfdanarson O, Zoega H, Aagaard L, Bernardo M, Brandt L, et al. (2017) International trends in antipsychotic use: A study in 16 countries, 2005-2014. Eur Neuropsychopharmacol 27: 1064-1076. Link: https://tinyurl.com/y7tufndm

Wani RA, Dar MA, Chandel RK, Rather YH, Haq I, et al. (2015) Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. Neuropsychiatric Disease and Treatment 11: 685-93. Link: https://tinyurl.com/ycxxwlaw

Pignon B, Tezenas du Montcel C, Carton L, Pelissolo A (2017) The place of antipsychotics in the therapy of anxiety disorders and obsessive-compulsive disorders. Curr Psychiatry Rep 19: 103-113. Link: https://tinyurl.com/ydxvc7yb

Greenblatt HK, Greenblatt DJ (2016) Use of antipsychotics for the treatment of behavioral symptoms of dementia. J Clin Pharmacol 56: 1048-1057. Link: https://tinyurl.com/yaccrv5a

FDA Public Health Advisory (2010). Deaths with antipsychotics in elderly patients with behavioral disturbances. Link: https://tinyurl.com/y7fr3sqy

Hennekens CH, DeMets D (2009) The need for large scale randomized evidence without undue emphasis on small trials, meta-analyses or subgroup analyses. JAMA 302: 2361-2362. Link: https://tinyurl.com/ycvpu8an

Hennekens CH, DeMets D (2011) Statistical association and causation: Contributions of different types of evidence JAMA 306: 1134-1136. Link: https://tinyurl.com/ycxqq9cm

Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, et al. 2006) CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease N Engl J Med 355: 1525-1538. Link: https://tinyurl.com/y8vd4tmw

De Deyn PP,Drenth AF,Kremer BP, Oude Voshaar RC, Van Dam D (2013) Aripiprazole in the treatment of Alzheimer's disease Expert Opin Pharmacother 14: 459-474. Link: https://tinyurl.com/yb8aurps